Biosimilars have the potential to dramatically reduce costs for both providers and patients, yet adoption remains uneven across therapeutic areas, payers, and provider settings. With biosimilar entrants accelerating and list-to-net dynamics shifting, stakeholders face a complex mix of formulary pressures, contracting strategies, supply variability, and clinical confidence gaps. At the same time, a looming “biosimilar void” for many upcoming loss-of-exclusivity biologics poses material risks to affordability, supply chain resilience, and long-term competition—impacting budgets and patient access.

This session will equip participants to analyze uptake and pricing trends across key molecules to inform procurement and formulary design; confront the top barriers to adoption with actionable tools that reduce prescriber hesitancy and streamline operational rollout; quantify real-world cost savings and downstream outcomes from successful implementations; and assess the strategic implications of pipeline gaps, including how to mitigate supply and cost risks when the majority of near-term LOE biologics lack biosimilar development. Attendees will leave with practical tactics to accelerate sustainable biosimilar adoption while protecting quality and access.

• Analyze biosimilar uptake patterns and pricing trends across molecules to identify optimal procurement and formulary strategies
• Address the top barriers holding back biosimilar adoption in your organization with practical tools to overcome prescriber hesitancy and streamline implementation.
• Examine proven cost-saving opportunities from real-world biosimilar adoption cases and their impact on healthcare system budgets and patient outcomes
• Address the strategic implications of biosimilar void: supply chain and cost risks when 90% of biologics facing loss of exclusivity in the next 10 years have no biosimilar in development